Navigation Links
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Date:5/20/2008

om baseline was greater in the rufinamide therapy group than in the placebo group (32.7% vs 11.7%) (p<0.002). The rufinamide-treated patients had 42.5% median percentage reduction in tonic-atonic seizure (drop attack) frequency per 28 days from baseline as compared with 1.4% increase in the placebo-treated patients (p<0.0001). The rufinamide group had a statistically significant improvement in seizure severity (p<0.005) and a higher percentage of patients who experienced at least a 50% reduction in tonic-atonic seizure frequency per 28 days compared with placebo (42.5% vs 16.7; p=0.002). The common adverse events reported by more than 10% of patients receiving rufinamide and at a higher frequency than in placebo-treated patients were somnolence (24.3% with rufinamide vs 12.5% with placebo) and vomiting (21.6% vs 6.3%).

About Rufinamide

Rufinamide is a structurally novel compound that acts as a broad-spectrum anticonvulsant originally discovered and developed by Novartis Pharma AG. The New Drug Application (NDA) is pending review for safety and efficacy with the U.S. Food and Drug Administration. Eisai acquired an exclusive worldwide license to develop, manufacture and market rufinamide for any human therapeutic use with the exception of bipolar mood disorder, anxiety disorders and ophthalmologic disorders from Novartis Pharma AG in 2004.

About LGS

It is estimated that the incidence of LGS ranges from 1,400 to 4,500 new cases each year in the United States. Symptoms of LGS include a variety of seizure types, with tonic-atonic seizures being the most common. Atonic seizures (rapid loss of muscle tone and consciousness), and tonic seizures (where muscles contract continuously typically producing a stiffening of the legs and arms) lead to the sudden falls seen in LGS patients known as 'drop attacks.' Absence seizures (staring spells) and myoclonic seizures (sudden muscle jerks) are also commonly observed. All children with LGS will experience
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... SAN DIEGO, April 30, 2015  Tandem Diabetes Care ® ... and manufacturer of the t:slim ® and t:flex™ Insulin ... March 31, 2015. In comparing the first ... , Sales grew 53 percent to $12.3 million from $8.1 ... 2,487 pumps from 1,723 pumps "Our investment in ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: DRRX ) announced today financial results for ... million and net loss was $4.9 million for the ... total revenues of $6.3 million and net loss of ... 2014.At March 31, 2015, we had cash and investments ... $34.9 million at December 31, 2014.  Subsequent to quarter-end, ...
Breaking Medicine Technology:Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... 2012  At the 2012 American Association of Neurological ... the Miami Beach Convention Center, Elekta (booth #725) ... Knife® Perfexion™ that promise to enhance information ... us the opportunity to demonstrate to neurological surgeons ...
... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
Cached Medicine Technology:Elekta to Unveil New Neuroscience Solution for Leksell Gamma Knife at 2012 AANS Meeting 2Mylan Launches First Generic Version of Lescol® Capsules 2
(Date:5/3/2015)... 03, 2015 It is not too late to ... Walk in Memory of Lissa Anne Been in Arnold, Missouri ... great family-friendly event to honor her loving memory. It has benefited ... , Just having turned 37, Lissa suffered a brain aneurysm ... August 24, 2012. This event is designed to serve as a ...
(Date:5/2/2015)... 02, 2015 “ ActOn ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... connected with organizations to make a difference. , In this ... few things that aren’t about money, which is why those ...
(Date:5/2/2015)... Liverpool, Ohio (PRWEB) May 02, 2015 ... East Liverpool City Hospital (ELCH) gathered to celebrate improvements ... of River Valley Health Partners (RVHP), had zero acquired ... zero urinary catheter associated infections. ELCH was also recently ... , The management team at ELCH credited the teamwork ...
(Date:5/1/2015)... (PRWEB) May 02, 2015 IDLife LLC, ... is proud to announce the addition of its newest ... is a life long athlete, growing up in gymnastics ... after college by becoming a personal trainer and helping ... the face of several TV shows highlighting her stunning ...
(Date:5/1/2015)... Va. (PRWEB) May 01, 2015 The ... nation’s leading nonprofit authority on the use of health ... as a key contributing resource to the United States ... use of electronically readable cards in Medicare. The report, ... and Providers ” was released to the public on ...
Breaking Medicine News(10 mins):Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... New Single ... People to Sign Up to Donate Life - New CD - No Regrets In Stores ... Beverly Hills, ... smash with the song "I Swear," is returning to recording and performing after a seven-year ...
... , Prostitution research takes to the ... Aug. 25 Dallas prostitutes are getting a chance to ... Police Department, Dallas County Sheriff,s Office, Dallas County Commissioner,s Office, ... and Homeward Bound, which serves as the lead for more ...
... too little is known about these ,in situ, malignancies, experts ... of women with breast cancer in situ in the United States ... 2016 that number is expected to increase to more than 1 ... of newly diagnosed breast cancers. It is the early stage of ...
... , , SAN DIEGO, Aug. ... in the S&P 500 index following the company,s planned spinoff from Cardinal ... index on Sept. 1, coinciding with its first day of regular-way trading ... , "Our inclusion in the S&P 500 is a ...
... , TUESDAY, Aug. 25 (HealthDay News) -- In a major ... that saliva contains at least 50 microRNAs that could aid ... in the saliva of 50 people with oral squamous cell ... microRNAs that may be associated with oral cancer. , The ...
... long-term tamoxifen use among breast cancer survivors decreases their ... of second breast cancer, such use is associated with ... aggressive, difficult-to-treat type of cancer in the breast opposite, ... Christopher Li, M.D., Ph.D., and colleagues at Fred Hutchinson ...
Cached Medicine News:Health News:R&B / Pop Vocal Quartet All-4-One Makes 7-Year Comeback 2Health News:R&B / Pop Vocal Quartet All-4-One Makes 7-Year Comeback 3Health News:UNTHSC Collaborates With Law Enforcement to Provide Alternatives to Dallas Prostitutes 2Health News:UNTHSC Collaborates With Law Enforcement to Provide Alternatives to Dallas Prostitutes 3Health News:More Women Surviving After Early Breast Cancer 2Health News:More Women Surviving After Early Breast Cancer 3Health News:CareFusion Corp to be Included in S&P 500 Index 2Health News:Saliva May Help Spot Oral Cancer Early 2Health News:Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer 2
... basic Thermomixer is a compact model that ... x 1.5 ml tubes. Impressive features of ... design, and high stabilityeven at maximum mixing ... gentle to vigorous mixing, including intermittent mixing; ...
... ug Strept. 25 ug Fungizone ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
Medicine Products: